CT26-Pd-l1 Knockout Tumor Cell Line

Knockout Immune Checkpoint Cell Lines

Design of the CT26-Pd‑l1 Knockout

The CT26.WT cell line was derived and subcloned from Balb/c murine colon carcinoma and forms tumors at high frequency when inoculated subcutaneously. We generated CT26-Pd-l1 Knockout clonal cell lines invalidated for murine Pd-l1 (Cd274).

Applications in immuno-oncology

The CT26-Pd-l1 Knockout clones can be used for target validation and mechanistic studies.

Humanized CT26-hPD-L1 cell line:
Use our humanized CT26-hPD-L1 cell line for in vivo tumor growth assays in syngeneic models.

 

Request a quote here to get pricing, offers and CT26-Pd-l1 Knockout model information by phone or email.

  

CT26-Pd-l1 Knockout features

  • Invalidated for murine Pd-l1
  • Form tumors upon subcutaneous injection in fully immunocompetent mice

CT26-Pd-l1 Knockout validation*

CT26-Pd-l1 KO ICP model validation 1

Invalidation of murine Pd-l1 in CT26-Pd-l1 Knockout cells

Expression analysis by FACS. mPd-l1 expression in CT26‑Pd‑l1 Knockout (KO) clone and parental cell line.

CT26-Pd-l1 KO cells form tumors in vivo

CT26-Pd-l1 KO ICP model validation 2aCT26-Pd-l1 KO ICP model validation 2b

Wild-type Balb/c mice were injected (s.c.) with 1x105 CT26.WT (A) or CT26-Pd-l1 KO (B) cells. Tumor growth was measured every 2 to 3 days. Tumor size (mm3) = (width2 x length)/2. 8 mice (mixed gender) were injected per group, with 8 mice developing tumors for CT26.WT and CT26-Pd-l1 KO clone 1 injected groups, and 7 for CT26-Pd-l1 KO clone 2 injected group.

* For more validation data please contact us.

Ready to be shipped to your lab

  • Biosafety level BSL1, according to ATCC guidelines (parental cell line provider)
  • Studies can be carried out at your site or at your favorite CRO
  • Models provided with FTO on patent-protected technologies used for model generation
Are you looking for another target?
Please contact us.